![]() Monitor patients frequently for signs and symptoms of neurological impairment. optimal timing between the administration of ELIQUIS and neuraxial procedures is not known.a history of spinal deformity or spinal surgery.a history of traumatic or repeated epidural or spinal punctures.concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: Consider these risks when scheduling patients for spinal procedures. ![]() These hematomas may result in long-term or permanent paralysis. (B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant. (A) Premature discontinuation of any oral anticoagulant, including ELIQUIS ® (apixaban), increases the risk of thrombotic events. WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA SELECTED IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION MORE IMPORTANT SAFETY INFORMATION
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |